Vena Cava Filter for All Patients After Severe Trauma

Until today, there was no evidence warranting the early implantation of a vena cava filter for the reduction of the risk of pulmonary embolism in patients with severe trauma and contraindication to prophylactic anticoagulation.

This article, soon to be published in the New England Medical Journal (NEJM), brings us such evidence and we surrender to it. Early prophylactic placement of a vena cava filter after severe trauma did not reduce the incidence of symptomatic pulmonary embolism or death at 90 days compared with no implantation of a filter.

This multicenter controlled trial enrolled 240 patients with severe trauma (Injury Severity Score >15; scores range from 0 to 75, and the highest the score, the highest the severity]) who had a contraindication to anticoagulation, and randomized them to filter implantation within the first 72 hours after admission vs. no implantation.


Read also: New Promising Alternatives for Mitral Regurgitation.


The primary endpoint was a composite of symptomatic pulmonary embolism at 8 to 90 days in the subgroup of patients who survived at least 7 days and who did not receive prophylactic anticoagulation during that time.

The mean age was 39 years old and the mean Injury Severity Score was 27.

Early filter implantation did not result in lower incidence of the primary endpoint (13.9% in the vena cava filter group vs. 14.4% in the control group; p = 0.98).

No patient in the filter group developed pulmonary embolism while 5 patients (14.7%) in the control group, including one who died, did experience such complication. Entrapped thrombus was found in the filter in 6 patients.

Conclusion

Early prophylactic placement of a vena cava filter in patients with severe trauma did not result in a lower incidence of symptomatic pulmonary embolism or death at 90 days vs. no filter implantation in patients with contraindication to prophylactic anticoagulation.

Original Title: A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.

Reference: Kwok M. Ho et al. N Engl J Med. 2019 Jul 7. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...